A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2015
At a glance
- Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 24 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 28 Apr 2013 Interim results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 23 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History